Diaz-Manera, J, Kishnani, PS, Kushlaf, H, Ladha, S, Mozaffar, T, Straub, V, Toscano, A, Van der Ploeg, AT, Berger, KI, Clemens, PR, Chien, YH, Day, JW, Illarioshkin, S, Roberts, M, Attarian, S, Borges, JL, Bouhour, F, Choi, YC, Erdem-Ozdamar, S, Goker-Alpan, O, Kostera-Pruszczyk, A, Haack, KA, Hug, C, Huynh-Ba, O, Johnson, J, Thibault, N, Zhou, TY, Dimachkie, MM, Schoser, B. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. LANCET NEUROLOGY. 2021; 20(12)DOI:10.1016/S1474-4422(21)00241-6. PMID:34800399. IF:59.935(Q1/1D).

Sampedro, F, Martinez-Horta, S, Perez-Perez, J, Perez-Gonzalez, R, Horta-Barba, A, Campolongo, A, Aracil-Bolanos, I, Gomez-Anson, B, Kulisevsky, J. Interaction between sex and neurofilament light chain on brain structure and clinical severity in Huntington's disease. Annals of Clinical and Translational Neurology. 2021; 8(12)DOI:10.1002/acn3.51460. PMID:34761569. IF:5.430(Q1/3D).

Aracil-Bolanos, I, Sampedro, F, Pujol, J, Soriano-Mas, C, Gonzalez-de-Echavarri, JM, Kulisevsky, J, Pagonabarraga, J. The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?. HUMAN BRAIN MAPPING. 2021; 42(17)DOI:10.1002/hbm.25650. PMID:34510640. IF:5.399(Q1/3D).

Garcia, DS, Rios, LN, Fonticoba, TD, Bartolome, CC, Roca, LG, Painceiras, MF, Miro, CM, Canfield, H, Jesus, S, Aguilar, M, Pastor, P, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, Puente, V, Dotor, J, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JMC, Alonso, PS, Losada, MAG, Ariztegui, NL, Gaston, I, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Redondo, RA, Ordas, C, Diaz, LLM, McAfee, D, Martinez-Martin, P, Mir, P. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics. 2021; 11(12)DOI:10.3390/diagnostics11122380. PMID:34943619. IF:3.992(Q2/4D).